GEMCITABINE-DOCETAXEL VERSUS CISPLATIN-GEMCITABINE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL-CELL LUNG CANCER

被引：0
|
作者：
Al-Gizawy, S. M. [1 ]
Mostafa, H. G. [1 ]
机构：
[1] Assiut Univ, Dept Clin Oncol, Fac Med, Assiut, Egypt
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/j.ejca.2014.03.065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P0021
引用
收藏
页码：E15 / E15
页数：1
相关论文
共 50 条
  • [1] Docetaxel-gemcitabine versus cisplatin-gemcitabine plus sequential docetaxel in the first-line treatment of metastatic non-small cell lung cancer (NSCLC): interim results of a randomized Phase II trial
    Binder, Daniel
    Beinert, Thomas
    Schweisfurth, Hans
    Grah, Christian
    Temmestfeld-Wollbrueck, Bettina
    Schaeper, Christoph
    Mueller-Hagen, Gerit
    Schuermann, Dirk
    Suttorp, Norbert
    ANNALS OF ONCOLOGY, 2004, 15 : 178 - 178
  • [2] Gemcitabine-docetaxel versus cisplatin.-vinorelbine in advanced or metastatic non-small-cell lung cancer:: a phase III study addressing the case for cisplatin
    Pujol, JL
    Breton, JL
    Gervais, R
    Rebattu, P
    Depierre, A
    Morére, JF
    Milleron, B
    Debieuvre, D
    Castéra, D
    Souquet, PJ
    Moro-Sibilot, D
    Lemarié, E
    Kessler, R
    Janicot, H
    Braun, D
    Spaeth, D
    Quantin, X
    Clary, C
    ANNALS OF ONCOLOGY, 2005, 16 (04) : 602 - 610
  • [3] DOCETAXEL AND GEMCITABINE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: AN EXAMPLE OF TRANSLATIONAL RESEARCH
    Zoli, Wainer
    Cecconetto, Lorenzo
    Dall'Agata, Monia
    Riva, Nada
    Tassinari, Davide
    Calpona, Sebastiano
    Rosti, Giovanni
    Piancastelli, Alessandra
    Frassineti, Giovanni Luca
    ANNALS OF ONCOLOGY, 2004, 15 : 29 - 30
  • [4] Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial
    D. Binder
    H. Schweisfurth
    C. Grah
    C. Schäper
    B. Temmesfeld-Wollbrück
    G. Siebert
    N. Suttorp
    T. Beinert
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 143 - 150
  • [5] Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: results of a multicentre randomized phase II trial
    Binder, D.
    Schweisfurth, H.
    Grah, C.
    Schaeper, C.
    Temmesfeld-Wollbrueck, B.
    Siebert, G.
    Suttorp, N.
    Beinert, T.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 143 - 150
  • [6] First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial
    Gridelli, Cesare
    Ciardiello, Fortunato
    Gallo, Ciro
    Feld, Ronald
    Butts, Charles
    Gebbia, Vittorio
    Maione, Paolo
    Morgillo, Floriana
    Genestreti, Giovenzio
    Favaretto, Adolfo
    Leighl, Natasha
    Wierzbicki, Rafal
    Cinieri, Saverio
    Alam, Yasmin
    Siena, Salvatore
    Tortora, Giampaolo
    Felletti, Raffaella
    Riccardi, Ferdinando
    Mancuso, Gianfranco
    Rossi, Antonio
    Cantile, Flavia
    Tsao, Ming-Sound
    Saieg, Mauro
    Santos, Gilda da Cunha
    Piccirillo, Maria Carmela
    Di Maio, Massimo
    Morabito, Alessandro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (24) : 3002 - 3011
  • [7] A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma
    Casal Rubio, Joaquin
    Vazquez, S.
    Vazquez, F.
    Amenedo, M.
    Firvida, J. L.
    Mel, J. R.
    Huidobro, G.
    Alvarez, E.
    Lazaro, M.
    Alonso, G.
    Fernandez, I.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 379 - 384
  • [8] A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma
    Joaquín Casal Rubio
    S. Vázquez
    F. Vázquez
    M. Amenedo
    J. L. Fírvida
    J. R. Mel
    G. Huidobro
    E. Álvarez
    M. Lázaro
    G. Alonso
    I. Fernández
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 379 - 384
  • [9] Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer
    Butts, Charles A.
    Bodkin, David
    Middleman, Edward L.
    Englund, Craig W.
    Ellison, David
    Alam, Yasmin
    Kreisman, Harvey
    Graze, Peter
    Maher, James
    Ross, Helen J.
    Ellis, Peter M.
    McNulty, William
    Kaplan, Edward
    Pautret, Virginie
    Weber, Martin R.
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (36) : 5777 - 5784
  • [10] Docetaxel/gemcitabine vs. cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: Results of a randomised phase II trial
    Binder, D
    Schweisfurth, H
    Grah, C
    Schäper, C
    Temmesfeld-Wollbrück, B
    Siebert, G
    Suttorp, N
    Beinert, T
    LUNG CANCER, 2005, 49 : S237 - S237
12345